The 20th annual Rice Business Plan Competition took place virtually from June 17 to 19 and awarded over $1.2 million in investment and cash prizes. Photo courtesy of Rice University

For the 20th year, the Rice Business Plan Competition has awarded prizes and investments to student-led startups from around the ward. While this year's competition was postponed and virtually held, the show went on with 42 startups pitching virtually June 17 to 19.

After whittling down the 42 startups to seven finalists, the RBPC judges named the winners. And, this year, all seven finalists walked away with a monetary prize. Here's how the finalists cleaned up.

  • Aurign, which provides publishing services for recording artists and record labels, from Georgia State University, won first place and the $350,000 grand prize from GOOSE Capital. Aurign also won RG Advisory Partners' prize of $25,000, bringing the company's total to $375,000 won.
  • Coming in second place with a $100,000 investment prize (awarded by Finger Interests, Anderson Family Fund, Greg Novak, and Tracy Druce) was Dartmouth College's nanopathdx, which is creating diagnostic tools for chronic and infectious diseases. Nanopathdx won two other monetary prizes — the $25,000 Spirit of Entrepreneurship Prize from Pearland Economic Development and Ncourage's $25,000 award focused on female entrepreneurs — for a total of $150,000 won. The company also won the Palo Alto Software Live Plan award and an award from SheSpace.
  • Harvard University's Fractal — a cloud computing tech company that enables powerful remote work tools — won third place and a $50,000 investment from Finger Interests, Anderson Family Fund, Greg Novak, and Tracy Druce. The company also won an $100,000 investment from the Houston Angel Network, bringing their total prize to $150,000.
  • In fourth place was RefresherBoxx from RWTH Aachen University in Germany. The company has created disinfecting devices for clothing and recently pivoted to create a COVID-19 application. The startup won a $5,000 prize sponsored by Norton Rose Fulbright for placing in the finals, but also walked away with a $100,000 investment from TiE Houston Angels, bringing the startup's total prize money to $105,000.
  • The University of Chicago's Beltech, which has created a safer, longer lasting battery, won fifth place and a $5,000 award sponsored by EY. The company also won an $100,000 investment from the Houston Angel Network, bringing the total amount won to to $105,000.
  • Cardiosense from Northwestern University, which has created a wearable heart monitor device, took sixth place in the competition and won a $5,000 award sponsored by Chevron Technology Ventures. Cardiosense also won two other monetary prizes — TMC Innovation's $100K TMC Healthcare Innovation investment and NASA's $25,000 Human Health and Performance Award — bringing the total amount won to $130,000. The company also won OFW Law's prize.
  • Relavo, a safer home dialysis treatment company from Johns Hopkins University, came in seventh place and won a $5,000 prize sponsored by Shell Ventures. Relavo also won three other monetary prizes — the $25,000 Pediatric Device Prize from the Southwest National Pediatric Device Consortium, Ncourage's $25,000 award focused on female entrepreneurs, and Polsinelli's $15,000 technology prize — bringing the startup's total prize money to $70,000.
Some of the competition's participating startups outside of the seven finalists won monetary prizes. Here's a list of those.
  • BIOMILQ, a female-founded startup out of Duke University that can cultivate breast milk outside of the body, won The Artemis Fund's $100,000 prize.
  • The University of Maryland's Algen Air — a natural air purifier that uses algae to filter air — won NASA's $25,000 Space Exploration Award.
  • SlumberFlow — a sleep apnea treatment device from the University of Michigan — won the the $25,000 Pediatric Device Prize from the Southwest National Pediatric Device Consortium.
  • Rice University's own EVA, which streamlines vascular access for medical professionals, won the Texas Business Hall of Fame's $25,000 prize.
  • Contraire — a predictive analysis control system for aeration process within municipal wastewater treatment plants — from Oklahoma State University won Polsinelli's $15,000 Energy Innovation prize.
While not ready to name investment recipients at the virtual event, the Owl Investment Group announced they will be inviting some companies to pitch to them directly.
Additional non-monetary prizes included:
  • Capital Factory's Golden Ticket prize to EVA from Rice University, NanoCare from Texas State University, and SeebeckCell Technologies from the University of Texas at Arlington.
  • Mercury Fund's Elevator Pitch winners included: KnoNap from Georgetown University (first place), Steeroflex from the University of California San Diego (second place), Encapsulate from the University of Connecticut (third place), RefresherBoxx (fourth place), and NanoCare from Texas State University (fifth place).
The virtual event wrapped up with the announcement of the 21st annual RBPC, which is set for April 8 to 10 next year.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”